EU/3/21/2464: Orphan designation for the treatment of follicular lymphoma

tisagenlecleucel

Overview

This medicine was designated as an orphan medicine for the treatment of follicular lymphoma in the European Union on 19 July 2021.

This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to the stage where they can apply for a marketing authorisation.

Orphan designation does not mean the medicine is available or authorised for use. All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.

During the medicine's development, doctors may be able to enrol patients in clinical trials investigating the medicine. For information on ongoing clinical trials in the EU, see:

Key facts

Active substance
tisagenlecleucel
Intended use
Treatment of follicular lymphoma
Orphan designation status
Positive
EU designation number
EU/3/21/2464
Date of designation
19/07/2021
Sponsor

Novartis Europharm Limited
Vista Building
Elm Park       
Merrion Road
Dublin 4 D04 A9N6
Tel. +41 613 241 111
E-mail: orphan.enquiries@novartis.com

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Kymriah at the time of change to the terms of the marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the PDF icon orphan medicine assessment report .

Update history

DateUpdate
April 2022Tisagenlecleucel for treatment of follicular lymphoma has been authorised in the EU as Kymriah since 29 April 2022.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating